Prolonged survival with personalized immunotherapy (AGS-003) in combination with sunitinib in unfavorable risk metastatic RCC (mRCC)

被引：9

作者：

Amin, Asim

Dudek, Arkadiusz

Logan, Theodore

Lance, Raymond S.

Holzbeierlein, Jeffrey M.

Master, Viraj A.

Pal, Sumanta Kumar

Knox, Jennifer J.

Karsh, Lawrence Ivan

Plessinger, Doug

Nicolette, Charles A.

Figlin, Robert A.

机构：

[1] Carolinas Med Ctr, Charlotte, NC 28203 USA

[2] Univ Minnesota, Div Hematol Oncol & Transplantat, Minneapolis, MN USA

[3] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA

[4] Urol Virginia, Norfolk, VA USA

[5] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA

[6] Emory Univ, Atlanta, GA 30322 USA

[7] City Hope Natl Med Ctr, Duarte, CA 91010 USA

[8] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

[9] Urol Ctr Colorado, Denver, CO USA

[10] Argos Therapeut Inc, Durham, NC USA

[11] Cedars Sinai Med Ctr, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA

来源：

关键词：

D O I：

10.1200/jco.2013.31.6_suppl.357

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

357

引用

页数：1